Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AS03-Adjuvanted H7N9 Influenza Vaccine in Adults
NCT04789577Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2021
- Primary completion
- Sep 2022
- Modality
- Prophylactic Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in avian influenza A (H7N9) (7 arms), sponsored by GSK. Primary endpoints: Percentage of Seroprotected Participants for Anti-hemagglutination Inhibition (HI) Antibodies Against Vaccine-homologous H7N9 at Day 43, Percentage of Seroconverted Participants for Anti-HI Antibodies Against Vaccine-homologous H7N9 at Day 43 and 6 more. Started Mar 2021; status: completed.
02
Conditions
avian influenza A (H7N9)
Beyond the preview
Go deeper on NCT04789577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789577.